The Q3 2016 earnings report for UK based small cap cannabinoid stock GW Pharmaceuticals PLC (NASDAQ: GWPH) is scheduled for before the market opens Tuesday (August 9th). GW Pharmaceuticals PLC had tumbled earlier in the year on reports about disclosures concerning material weaknesses in its accounting practices related to clinical trial costs and milestones. The Company also had a number of stumbles last year with the failure of three phase 3 trials of its THC drug Sativex for cancer pain and a disappointing mid stage trial readout for the treatment of schizophrenia.
On the other hand, shares soared in late June when GW Pharmaceuticals PLC announced positive results from a Phase 3 clinical trial of its investigational medicine Epidiolex (cannabidiol or CBD) for the treatment of Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy. In addition and a few weeks ago, GW Pharmaceuticals PLC also announced the closing of an offering